Protalix Biotherapeutics, Inc. (PLX) — 10-Q Filings

10-Q Filings (6)

• Protalix Narrows 9-Month Loss to $1.1M on Revenue Growth — Nov 13, 2025 Risk: medium
  Protalix BioTherapeutics, Inc. reported a net loss of $1.1 million for the nine months ended September 30, 2025, a significant improvement from the $3.56 millio
• Protalix Narrows H1 Loss on Strong Revenue Growth, Q2 Turns Profit — Aug 14, 2025 Risk: medium
  Protalix BioTherapeutics, Inc. (PLX) reported a significant increase in total revenue for the six months ended June 30, 2025, reaching $25.77 million, up from $
• Protalix BioTherapeutics Files Q1 2025 10-Q — May 9, 2025 Risk: medium
  Protalix BioTherapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operational updates.
• Protalix BioTherapeutics Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Protalix BioTherapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial position, including changes i
• Protalix BioTherapeutics Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  Protalix BioTherapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the seco
• Protalix BioTherapeutics Files 10-Q for Period Ending March 31, 2024 — May 10, 2024 Risk: medium
  Protalix BioTherapeutics, Inc. (PLX) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Protalix BioTherapeutics reported financial results for the q

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX